Piper Sandler Keeps Their Buy Rating on Opko Health (OPK)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Opko Health (OPK – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $1.35.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

According to TipRanks, Tenthoff is an analyst with an average return of -23.8% and a 24.19% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Capricor Therapeutics, and Dyne Therapeutics.

In addition to Piper Sandler, Opko Health also received a Buy from H.C. Wainwright’s Yi Chen in a report issued yesterday. However, on April 25, J.P. Morgan initiated coverage with a Hold rating on Opko Health (NASDAQ: OPK).

Based on Opko Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $183.64 million and a net profit of $14.03 million. In comparison, last year the company earned a revenue of $181.9 million and had a GAAP net loss of $66.51 million

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPK in relation to earlier this year. Last month, Phillip Frost, the CEO & Chairman of OPK bought 125,000.00 shares for a total of $183,750.00.